Dengue vaccine candidate: Takeda announces data from 18-month interim Phase 2 trial
by Press Release from Outbreak News Today on (#377DX)
Takeda Pharmaceutical Company Limited today announced that data from an 18-month interim analysis of the ongoing Phase 2 DEN-204 trial of its live, attenuated tetravalent dengue vaccine candidate, TAK-003 (also referred to as TDV), have been published in The Lancet Infectious Diseases. The results of this interim analysis, a pre-planned evaluation of data from an ongoing trial, show ["]
The post Dengue vaccine candidate: Takeda announces data from 18-month interim Phase 2 trial appeared first on Outbreak News Today.